Experimental models for nephropathy

Nephropathy is a leading cause of morbidity and mortality and its prevalence is Continuously increasing in industrialised nations. Nephropathy is characterised to varying degrees by nodular glomerulosclcrosis, glomerular basement membrane thickness and mesangial expansion, leading to a decline in glomerular filtration rate, persistent elevated albuminuria, elevated arterial blood pressure and fluid retention. Hyperglycaemia, hyperlipidaemia and hypertension are considered to be the major risk factors implicated in the progression of nephropathy. Various signalling systems, such as vasoconstrictor peptides, inflammatory mediators, growth factors and adhesion molecules, are involved in the pathogenesis of nephropathy. At present, no promising therapy is available to treat patients with nephropathy due to lack Of understanding of signalling culprits involved in the pathogenesis of 1-nephropathy. Animal models are being developed to better understand the disease pathogenesis and develop drugs for nephropathy. In the present review, we have discussed various animal models for nephropathy, which may open vistas for developing new drugs to treat nephropathy.